Hormone Sensitive Advanced Prostate Cancer Treatment Market to reach US$ 24.94 Billion by 2033, rising at a 7.2% CAGR | Analysis by Future Market Insights, Inc. 2023/06/05 14:23:00 Accesswire
NEWARK, DE / ACCESSWIRE / June 5, 2023 / The global hormone-sensitive advanced prostate cancer treatment market is expected to be worth US$12.44 Billion in 2023. According to Future Market Insights, the market will grow at a 7.2% CAGR until 2033, with a market value of US$ 24.94 Billion. The primary goal of the key providers is translating science into innovative oncology medicines for helping people with cancer globally, where they commit to potentially bring new hope driving the purpose, and supporting accessibility through their cancer medicines. Drivers and Challenges have an Impact on Market Dynamics, which can Impact Businesses. Find more details in your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-17047 Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to the recurrence or spread of cancer after initial treatment. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment.
WHO to seek global certificate system, inspired by EU’s Covid pass 2023/06/05 13:04:27 Business Recorder
GENEVA: The World Health Organization will use the European Union’s digital Covid pass as a basis for a global health certification system, according to a new partnership deal agreed Monday. WHO chief Tedros Adhanom Ghebreyesus and EU health commissioner Stella Kyriakides signed what they described as a “landmark” agreement in Geneva. “The Covid-19 pandemic highlighted the value of digital health solutions in facilitating access to health services,” Tedros said at the signing ceremony. He said the EU’s Covid certificate would now be transformed into “a global public good”, as a first step in the creation of a global digital health certification network. The network will expand to include things like digitised international routine vaccination cards, he said. Covid no longer a global health emergency: WHO It will be aimed to help protect people from health threats, including possible future pandemics, and facilitate global mobility, the WHO and the EU said in a statement. This “will be an important part of our efforts to strengthen health systems and to support our member states to prepare better for the next epidemic or pandemic,” Tedros said. “The network could also play a crucial role in cross-border humanitarian situations by ensuring people have access to their health records and credentials as they move across borders due to conflict, the climate crisis and other emergencies.” ‘Privacy is key’ The EU Covid certificate, made available on paper or digitally, has been used by travellers moving around inside the bloc to show their Covid vaccination or test status.
Could Pfizer Have an Ozempic Killer on the Way? 2023/06/05 09:55:00 The Motley Fool
Pfizer hopes to compete in what could be a $100 billion to $200 billion market.
Novo Nordisk, Lilly facing increased competition in obesity drug market 2023/06/04 18:53:53 Seeking Alpha
Amgen (AMGN) and Pfizer (PFE) could soon be snacking on Novo Nordisk (NVO) and Eli Lilly''s (LLY) lunch in the anti-obesity market, says Morningstar. Read more here.
Pfizer relaunches Eliquis to prevent stroke 2023/06/03 07:33:00 BusinessDay
Pfizer has relaunched Eliquis, an anticoagulant to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults. With hypertension as the number one heart disease affecting about 10 million adults in Nigeria and only about one-third […] read more Pfizer relaunches Eliquis to prevent stroke
How to get the omicron COVID-19 booster shot 2022/09/02 18:26:44 Deseret
A syringe is checked prior to a booster vaccine by a Nomi Health worker in West Valley City on July 14, 2022. Jeffrey D. Allred, Deseret News The new omicron-targeted COVID-19 booster shots may be shipping Friday, but aren’t expected to be widely available until after the Labor Day holiday. The first updated COVID-19 booster doses — also known as “bivalent vaccines” — from Pfizer and Moderna won quick approval this week from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention to be ready for another potential COVID-19 surge this fall. Related Forget herd immunity. Best case may be ‘herd safety,’ new COVID-19 study suggests Here’s what you need to know: Who can get an omicron booster shot? Teens and adults who have been fully vaccinated for at least two months. Fully vaccinated means having received the first two doses of the original Pfizer or Moderna vaccine, or the recently approved Novavax vaccine , or the single dose of the Johnson & Johnson vaccine that’s no longer recommended for most people Teens and adults who have waited at least two months since their most recent booster shot Pfizer’s omicron booster is authorized for people 12 and older Modern’s omicron booster is authorized for people 18 and older Related Will Novavax be the ‘perfect option’ for those still unvaccinated against COVID-19?
Moderna, BioNTech Dip Despite CDC Green-Light For Updated Covid Shots 2022/09/02 18:20:16 Investor''s Business Daily
The CDC green-lighted updated Covid booster shots from Pfizer with BioNTech and Moderna, but vaccine stocks dipped Friday.
Worldwide: Moderna Sues Pfizer / BioNTech For COVID Vaccine Patent Infringement - Dennemeyer Group 2022/09/02 17:52:16 Mondaq
On August 26, 2022, biotechnology company Moderna filed lawsuits against pharmaceutical giant Pfizer and its German partner BioNTech for the alleged infringement of patented mRNA technology in the development of the "Comirnaty" COVID-19 vaccine.
Landmark First Peer-Reviewed Study on Pfizer and Moderna Covid Vaccines Confirms ‘Excess Risk’ of Adverse Side Effects 2022/09/02 17:46:17 Trending Politics
A landmark peer-reviewed study appears to be the first of its kind to provide hard data on the “excess risk” of adverse […]
Moderna Has One Over Pfizer/BioNTech – but It’s Nothing to Do With Patent Infringement 2022/09/02 17:42:28 TipRanks
Forget Elon Musk vs. Twitter, there’s new beef on Wall Street. Back in 2020, as Covid-19 brought the world to a virtual standstill, pharma companies were focused on…
Officials: Millions Of Orders Placed For COVID Vaccines For Youngest 2022/06/09 14:52:00 Newsy
Watch Video Millions of COVID-19 vaccine doses have been ordered for small children in anticipation of possible federal authorization next week, White House officials say. The government allowed pharmacies and states to start placing orders last week, with 5 million doses initially available — half of them shots made by Pfizer and the other half the vaccine produced by Moderna, senior administration officials said. SEE MORE: FDA Advisers Back Novavax Vaccine As New U.S. Option As of this week, about 1.45 million of the 2.5 million available doses of Pfizer have been ordered, and about 850,000 of available Moderna shots have been ordered, officials said. More orders are expected in the coming days. Young children are the last group of Americans who have not been recommended to get COVID-19 vaccinations. Up to about 20 million U.S. children under 5 would become eligible for vaccination if the government authorizes one or both shots. It’s not clear how popular the shots will be. A recent survey suggests only 1 in 5 parents of young children would get their kids vaccinated right away.
Morning Brief: Top Financial Stories Dominating on Thursday, June 9 2022/06/09 12:27:09 Benzinga
Reuters Blackstone Closes In Crown Bid After Australia Approvals: Reuters Blackstone Inc (NYSE: BX ), the investment management company, is likely to take the reins of Australia’s Crown resorts after the country’s regulators approve the bid. The Blackstone - Crown Resorts Ltd buyout is expected to be about $6.3 billion. United States Helps To Keep Taiwanese Warships In Service The U.S. has cleared a possible $120 million sale of parts to assist Taiwan in maintaining its warships, which the island’s defense ministry said would help assure combat readiness in the face of China’s “frequent activities” near the island. The U. S. Defense Security Cooperation Agency stated that it had submitted the requisite certification to Congress following State Department approval for the sale, which was requested by Taiwan’s de facto embassy in Washington. State Street Might Tap Credit Suisse As Takeover Interest Credit Suisse Group AG (NYSE: CS ) could receive a takeover offer from U.S. financial giant State Street (NYSE: STT ), stated a media report a day earlier.
Pfizer And 3 Other Stocks Insiders Are Selling 2022/06/09 11:06:14 Benzinga
US stock futures traded mixed this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. Williams-Sonoma The Trade: Williams-Sonoma, Inc. (NYSE: WSM ) President WS Brand Ryan Ross sold a total of 10,400 shares at an average price of $127.42. The insider received around $1.33 million from selling those shares. What’s Happening: Morgan Stanley recently maintained Williams-Sonoma with … Full story available on Benzinga.com
Biden administration lays out its plan for Covid-19 vaccinations for children under 5 2022/06/09 09:09:34 CNN
The White House is announcing a Covid-19 vaccine rollout plan Thursday for children under 5, partnering with state and local governments, health care providers, federal pharmacy partners, national and community-based organizations and other entities to ship and distribute vaccines across the country following next week''s meeting of the FDA''s vaccine advisers -- who will review data on these vaccines from Pfizer and Moderna -- and expected authorization from the full FDA.